- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05025839
Neurological Outcome After SARS-CoV-2 Infection (ATTRACT)
Long-term Neurological Outcome After SARS-CoV-2 Infection
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
Tyrol
-
Innsbruck, Tyrol, Österreich, 6020
- Rekrutierung
- Medical University Innsbruck, Department of Neurology
-
Kontakt:
- Raimund Helbok, Priv.Doz. Dr.
- Telefonnummer: 81689 +43 50 504
- E-Mail: raimund.helbok@tirol-kliniken.at
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- (1) Patients of either sex, aged ≥18 years with
- (2) confirmed SARS-CoV-2 infection (according to the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection),
- (3) signed and dated declaration of consent by the patient according to ICH-GCP Guidelines,
- (4) being able to speak and understand the German language
Exclusion Criteria:
- (1) Pre-existing dementia,
- (2) confirmed pregnancy,
- (3) patients without the capacity to consent,
- (4) asymptomatic patients,
- (5) patients not presenting to the hospital
Specific Inclusion/exclusion criteria for the MRI substudy
Inclusion criteria:
- (1) Patients of either sex, aged ≥18 years with
- (2) confirmed SARS-CoV-2 infection (according to the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection),
- (3) signed and dated declaration of consent by the patient according to ICH-GCP Guidelines,
- (4) being able to speak and understand the German language
- (5) agree to participate for MRI
Exclusion criteria:
- (1) Pre-existing dementia,
- (2) confirmed pregnancy,
- (3) patients without the capacity to consent,
- (4) asymptomatic patients,
- (5) patients not presenting to the hospital
- (6) definite contraindication to MRI (e.g. pacemakers)
Controls Patients after pneumonia (Cpneum) We will enrol at least 50 hospitalized age- and sex matched patients with pneumonia based on disease severity during the acute disease as: (group One) hospitalized (moderate; n=25) and (group two) severe patients admitted to the ICU for mechanical ventilation (n=25).
Inclusion criteria:
- (1) Patients of either sex, aged ≥18 years with
- (2) bacterial pneumonia according to CDC criteria,
- (3) signed and dated declaration of consent by the patient according to ICH-GCP Guidelines, and
- (4) being able to speak and understand the German language,
- (5) agree to participate for MRI
Exclusion criteria:
- (1) Pre-existing dementia,
- (2) confirmed pregnancy,
- (3) patients without the capacity to consent,
- (4) definite contraindication to MRI (e.g. pacemakers)
Healthy referents (Chealthy) Currently n=38 MRI acquisitions of prospectively recruited healthy individuals are available, fulfilling the criteria of this proposal (age- and sex matched; same MR protocol). This cohort will be prospectively extended by n=42 to reach age and sex matched criteria.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Fallkontrolle
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
C healthy
Healthy control group
|
No Intervention takes place, Patients are being observed and classified according to disease severity
Andere Namen:
|
C pneum
Control group of patients who were hospitalised and diagnosed with pneumonia ( COVID-19 pneumonia excluded)
|
No Intervention takes place, Patients are being observed and classified according to disease severity
Andere Namen:
|
Mild
Outpatients presenting to the hospital with COVID-19
|
No Intervention takes place, Patients are being observed and classified according to disease severity
Andere Namen:
|
Moderate
In-patients with COVID-19 not requiring ICU admission
|
No Intervention takes place, Patients are being observed and classified according to disease severity
Andere Namen:
|
Severe
Patients with COVID-19 admitted to the ICU
|
No Intervention takes place, Patients are being observed and classified according to disease severity
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Prevalence of neurological manifestations in COVID-19 patients
Zeitfenster: 3-months
|
3-month prevalence of neurological manifestations in COVID-19 patients presenting to the hospital in comparison to control patients (Cpneum)
|
3-months
|
Prevalence of neurological manifestations in COVID-19 patients
Zeitfenster: 12-months
|
12-month prevalence of neurological manifestations in COVID-19 patients presenting to the hospital in comparison to control patients (Cpneum)
|
12-months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Association, prevalence and classification of neurologic manifestations with structural neuroimaging in hospitalised COVID-19 patients after 3-months.
Zeitfenster: 3-months
|
Association of neurologic manifestations (specifically neuropsychological deficits and smelling deficits) with structural neuroimaging (high-field MRI) in comparison to control patients (Cpneum).
Prevalence and classification of neuroimaging abnormalities in hospitalized COVID-19 patients in comparison to controls (Cpneum and Chealthy).
Other (exploratory) endpoints derived from the clinical database might be analyzed on data driven considerations 3-months after acute disease.
|
3-months
|
Association, prevalence and classification of neurologic manifestations with structural neuroimaging in hospitalised COVID-19 patients after 12-months.
Zeitfenster: 12-months
|
Association of neurologic manifestations (specifically neuropsychological deficits and smelling deficits) with structural neuroimaging (high-field MRI) in comparison to control patients (Cpneum).
Prevalence and classification of neuroimaging abnormalities in hospitalized COVID-19 patients in comparison to controls (Cpneum and Chealthy).
Other (exploratory) endpoints derived from the clinical database might be analyzed on data driven considerations 12-months after acute disease.
|
12-months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- KLI 986
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur SARS-CoV-2
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNoch keine Rekrutierung
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Noch keine Rekrutierung
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeAktiv, nicht rekrutierend
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionAbgeschlossen
-
Indiana UniversityAbgeschlossenSARS-CoV-2Vereinigte Staaten
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District Hospital und andere MitarbeiterAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossen
-
University Hospital, Montpelliersociete SkillCell - 97198 Jarry; CNRS Alcediag UMR9005 - societe Sys2Diag -...Abgeschlossen
-
Argorna Pharmaceuticals Co., LTDAbgeschlossen
-
Argorna Pharmaceuticals Co., LTDAbgeschlossen
Klinische Studien zur No Intervention
-
RTI InternationalNo Means No WorldwideAbgeschlossenSexuelle Gewalt | Geschlechtsspezifische GewaltSüdafrika
-
University of Illinois at ChicagoUniversity of Chicago; The Broad FoundationAbgeschlossenColitis ulcerosaVereinigte Staaten
-
King's College LondonMedical University of Graz; Radboud University Medical Center; Novo Nordisk A/S; Juvenile Diabetes Research Foundation und andere MitarbeiterAbgeschlossenDiabetes mellitus, Typ 2 | Hypoglykämie | Diabetes mellitus, Typ 1 | Hypoglykämie-WahrnehmungsstörungVereinigtes Königreich
-
Otsuka Pharmaceutical Factory, Inc.CelerionAbgeschlossen
-
Universitat Jaume IAbgeschlossen
-
Seoul National University HospitalSamsung Medical Center; Chosun University HospitalBeendetRadiofrequenz-Ablation | Mikrowellen-AblationKorea, Republik von
-
University of MinnesotaAbgeschlossen
-
University of ValenciaHospital de la RiberaUnbekannt
-
China National Center for Cardiovascular DiseasesUnbekannt
-
Catharina Ziekenhuis EindhovenAbgeschlossen